Is Rigel Pharmaceuticals Inc (RIGL) overvalued? · P/E 9.1, rev $179.3M
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
This page asks whether Rigel Pharmaceuticals Inc (RIGL) looks expensive on cached numbers — not a short thesis.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RIGL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RIGL stock page for the full model, not this heading.
Not investment advice.